Observation of clinical efficacy and its influence on quality of life of pemetrexed combined with nadaplatin for advanced NSCLC
10.3969/j.issn.1005-1678.2017.08.088
- VernacularTitle:培美曲塞联合奈达铂治疗晚期非小细胞肺癌的临床疗效及对患者生活质量影响观察
- Author:
Yi ZHOU
- Keywords:
pemetrexed;
nedaplatin;
NSCLC;
clinical efficacy;
quality of life
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(8):212-214,217
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the curative effect pemetrexed combined with nadaplatin for advanced NSCLC its impact on the quality of life. Methods 60 patients with advanced NSCLC were randomly divided into control group (30 cases) and observation group (30 cases). The control group was treated with pemetrexed and cisplatin,the observation group was treated with pemetrexed and nadaplatin. The treatment cycle was three weeks, and the efficacy and toxic reaction were evaluated after at least 2 cycles. The response rate (RR) and toxicity were evaluated according to RECIST and RTOG, respectively. The eastern cooperative oncology group-performance status (ECOG-PS) and the European organization for research and treatment of cancer QOL questionnaire (EORTC QLQ-C30) was used to evaluated and quality of life, respectively. And the follow-up was carried on after treatment. Results The scores of general health status, fatigue, nausea and vomiting in the observation group EORTC QLQ-C30 scale were better than those in control group (P<0.05); the occurrence rate of gastrointestinal reaction and hypodynamia was 30.0% and 20.0%, which was lower than those in control group of 86.7% and 43.3%. The overall survival rate (70.0% vs 73.3%) and median PFS (6.0 months vs 6.1 months) were not statistically different between the two groups. Conclusion Pemetrexed combined with nadaplatin is effective and tolerable for advanced NSCLC, and can significantly improve the quality of life of patients, and it is worthy of wide clinical use.
